Skip to main content
NCBI home page
Cancer Biomarkers: Section A of Disease Markers logoLink to Cancer Biomarkers: Section A of Disease Markers
. 2016 Mar 30;16(3):351–358. doi: 10.3233/CBM-160573

Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy

Yunhua Mao a, Ke Li a, Li Lu b, Jie Si-tu a, Minhua Lu a, Xin Gao a,*
PMCID: PMC13016504  PMID: 26889981

Abstract

OBJECTIVES:

This study was aimed to explore Cdc20 expression and its correlation with clinicopathological characteristics and biochemical recurrence (BCR) after laparoscopic radical prostatectomy (LRP) in clinically localized prostate cancer (PCa).

METHODS:

Cdc20 expression was examined by immunohistochemistry in 166 cases, including 60 cases of benign hyperplasia of prostate (BPH) patients treated by transurethral resection and 106 cases of consecutive PCa patients treated by LRP without neoadjuvant therapy in a single Chinese institution. The correlation with clinicopathological features and the predictive value for BCR were statistically analyzed.

RESULTS:

Cdc20 expression was detected in 52 (86.7%) BPH and 97 (91.5%) PCa samples, which was statistically insignificant (P= 0.323). The rate of patients with high expression of Cdc20 was 21.7% in BPH and 37.7% in PCa (P= 0.033). A correlation was revealed between Cdc20 expression and postoperative Gleason scores (P= 0.046), positive surgical margin (P< 0.001). BCR-free survival was significantly lower in patients with high Cdc20 expression than those with low Cdc20 expression (P= 0.018). Univariate analysis indicated pTstage, post operative Gleason score, seminal vesicle invasion, lymph node invasion, surgical margin and Cdc20 expression significantly influenced BCR. Multivariate analysis revealed that postoperative Gleason score, seminal vesicle invasion, lymph node invasion, surgical margin and Cdc20 expression were independent predictors for BCR. After stratified by Gleason score and surgical margin status, Cdc20 expression and lymph node invasion remained significant in Cox regression analysis.

CONCLUSIONS:

Overexpression of Cdc20 may serve as an independent predictor for BCR in patients of clinically localized PCa undergoing LRP without neoadjuvant therapy.

Keywords: Prostatic neoplasms, cell division cycle 20, biochemical recurrence, radical prostatectomy

Full Text

The Full Text of this article is available as a PDF (2.6 MB).

References

  • [1]. Siegel R., Ma J., Zou Z. and Jemal A., Cancer statistics, 2014, CA Cancer J Clin 64 (2014), 9-29. [DOI] [PubMed] [Google Scholar]
  • [2]. Amling C.L., Biochemical recurrence after localized treatment, Urol Clin North Am 33 (2006), 147-59, v. [DOI] [PubMed] [Google Scholar]
  • [3]. Quinn D.I., Henshall S.M., Haynes A.M., Brenner P.C., Kooner R., Golovsky D., Mathews J., O'Neill G.F., Turner J.J., Delprado W., Finlayson J.F., Sutherland R.L., Grygiel J.J. and Stricker P.D., Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models, J Clin Oncol 19 (2001), 3692-705. [DOI] [PubMed] [Google Scholar]
  • [4]. Spencer E.S., Johnston R.B., Gordon R.R., Luca J.M., Ussakli C.H., Hurtado-Coll A., Srivastava S., Nelson P.S. and Porter C.R., Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality, Prostate 73 (2013), 905-12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5]. Kattan M.W., Yu C., Salomon L., Vora K., Touijer K. and Guillonneau B., Development and validation of preoperative nomogram for disease recurrence within 5 years after laparoscopic radical prostatectomy for prostate cancer, Urology 77 (2011), 396-401. [DOI] [PubMed] [Google Scholar]
  • [6]. Punnen S., Freedland S.J., Presti, Jr. J.C., Aronson W.J., Terris M.K., Kane C.J., Amling C.L., Carroll P.R. and Cooperberg M.R., Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy, Eur Urol 65 (2014), 1171-7. [DOI] [PubMed] [Google Scholar]
  • [7]. Mackinnon A.C., Yan B.C., Joseph L.J. and Al-Ahmadie H.A., Molecular biology underlying the clinical heterogeneity of prostate cancer: an update, Arch Pathol Lab Med 133 (2009), 1033-40. [DOI] [PubMed] [Google Scholar]
  • [8]. Tapia-Laliena M.A., Korzeniewski N., Hohenfellner M. and Duensing S., High-risk prostate cancer: a disease of genomic instability, Urol Oncol 32 (2014), 1101-7. [DOI] [PubMed] [Google Scholar]
  • [9]. Kops G.J., Weaver B.A. and Cleveland D.W., On the road to cancer: aneuploidy and the mitotic checkpoint, Nat Rev Cancer 5 (2005), 773-85. [DOI] [PubMed] [Google Scholar]
  • [10]. Bharadwaj R. and Yu H., The spindle checkpoint, aneuploidy, and cancer, Oncogene 23 (2004), 2016-27. [DOI] [PubMed] [Google Scholar]
  • [11]. Kim S. and Yu H., Mutual regulation between the spindle checkpoint and APC/C, Semin Cell Dev Biol 22 (2011), 551-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12]. Silva P., Barbosa J., Nascimento A.V., Faria J., Reis R. and Bousbaa H., Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint, Cell Prolif 44 (2011), 391-400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13]. Weinstein J., Jacobsen F.W., Hsu-Chen J., Wu T. and Baum L.G., A novel mammalian protein, p55CDC, present in dividing cells is associated with protein kinase activity and has homology to the Saccharomyces cerevisiae cell division cycle proteins Cdc20 and Cdc4, Mol Cell Biol 14 (1994), 3350-63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14]. Yu H., Cdc20: A WD40 activator for a cell cycle degradation machine, Mol Cell 27 (2007), 3-16. [DOI] [PubMed] [Google Scholar]
  • [15]. Rajagopalan H. and Lengauer C., Aneuploidy and cancer, Nature 432 (2004), 338-41. [DOI] [PubMed] [Google Scholar]
  • [16]. Chang D.Z., Ma Y., Ji B., Liu Y., Hwu P., Abbruzzese J.L., Logsdon C. and Wang H., Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression, J Hematol Oncol 5 (2012), 15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17]. Mondal G., Sengupta S., Panda C.K., Gollin S.M., Saunders W.S. and S. Roychoudhury, Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer, Carcinogenesis 28 (2007), 81-92. [DOI] [PubMed] [Google Scholar]
  • [18]. Moura I.M., Delgado M.L., Silva P.M., Lopes C.A., do Amaral J.B., Monteiro L.S. and Bousbaa H., High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma, J Oral Pathol Med 43 (2014), 225-31. [DOI] [PubMed] [Google Scholar]
  • [19]. Choi J.W., Kim Y., Lee J.H. and Kim Y.S., High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer, Virchows Arch 463 (2013), 681-7. [DOI] [PubMed] [Google Scholar]
  • [20]. Kato T., Daigo Y., Aragaki M., Ishikawa K., Sato M. and Kaji M., Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients, J Surg Oncol 106 (2012), 423-30. [DOI] [PubMed] [Google Scholar]
  • [21]. Kim Y., Choi J.W., Lee J.H. and Kim Y.S., MAD2 and CDC20 are upregulated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the uterine cervix, Int J Gynecol Pathol 33 (2014), 517-23. [DOI] [PubMed] [Google Scholar]
  • [22]. Karra H., Repo H., Ahonen I., Loyttyniemi E., Pitkanen R., Lintunen M., Kuopio T., Soderstrom M. and Kronqvist P., Cdc20 and securin overexpression predict short-term breast cancer survival, Br J Cancer 110 (2014), 2905-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23]. Mertens F., Johansson B. and Mitelman F., Isochromosomes in neoplasia, Genes Chromosomes Cancer 10 (1994), 221-30. [DOI] [PubMed] [Google Scholar]
  • [24]. Uhlmann F., Wernic D., Poupart M.A., Koonin E.V. and Nasmyth K., Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast, Cell 103 (2000), 375-86. [DOI] [PubMed] [Google Scholar]
  • [25]. Li M., Fang X., Wei Z., York J.P. and Zhang P., Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice, J Cell Biol 185 (2009), 983-94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26]. Kidokoro T., Tanikawa C., Furukawa Y., Katagiri T., Nakamura Y. and Matsuda K., CDC20, a potential cancer therapeutic target, is negatively regulated by p53, Oncogene 27 (2008), 1562-71. [DOI] [PubMed] [Google Scholar]
  • [27]. Banerjee T., Nath S. and Roychoudhury S., DNA damage induced p53 downregulates Cdc20 by direct binding to its promoter causing chromatin remodeling, Nucleic Acids Res 37 (2009), 2688-98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28]. Yamanaka S., Campbell N.R., An F., Kuo S.C., Potter J.J., Mezey E., Maitra A. and Selaru F.M., Coordinated effects of microRNA-494 induce G(2)/M arrest in human cholangiocarcinoma, Cell Cycle 11 (2012), 2729-38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29]. Sun H.B., Chen X., Ji H., Wu T., Lu H.W., Zhang Y., Li H. and Li Y.M., miR494 is an independent prognostic factor and promotes cell migration and invasion in colorectal cancer by directly targeting PTEN, Int J Oncol 45 (2014), 2486-94. [DOI] [PubMed] [Google Scholar]
  • [30]. Wu W.J., Hu K.S., Wang D.S., Zeng Z.L., Zhang D.S., Chen D.L., L. Bai and Xu R.H., CDC20 overexpression predicts a poor prognosis for patients with colorectal cancer, J Transl Med 11 (2013), 142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31]. Lize M., Herr C., Klimke A., Bals R. and Dobbelstein M., MicroRNA-449a levels increase by several orders of magnitude during mucociliary differentiation of airway epithelia, Cell Cycle 9 (2010), 4579-83. [DOI] [PubMed] [Google Scholar]
  • [32]. Kang M., Jeong C.W., Choi W.S., Park Y.H., Cho S.Y., Lee S., Lee S.B., Ku J.H., Hong S.K., Byun S.S., Jeong H., Kwak C., Kim H.H., Lee E. and Lee S.E., Pre- and post-operative nomograms to predict recurrence-free probability in korean men with clinically localized prostate cancer, PLoS ONE 9 (2014), e100053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33]. Isbarn H., Wanner M., Salomon G., Steuber T., Schlomm T., Kollermann J., Sauter G., Haese A., Heinzer H., Huland H. and Graefen M., Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era, BJU Int 106 (2010), 37-43. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Biomarkers: Section A of Disease Markers are provided here courtesy of SAGE Publications

RESOURCES